Skyrizi 150 mg, lnjektionslösung in einer Fertigspritze

7680669440022 CH-66944 Fertigspritze
Skyrizi 150 mg, lnjektionslösung in einer Fertigspritze
Fiches Amavita / Sun Store / Coop Vitality

Article details

Package size
1
Selling units
1
Measure
Fertigspritze(n)
Galenic form
Fertigspritze
Galenic group
unbekannt

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
08/02/2026
Summary of Product Characteristics
Français
08/02/2026
Summary of Product Characteristics
Italien
08/02/2026

Detailed composition

Substance Quantity Type Category
risankizumabum
150.0 MG Substance Wirkstoff (Principe actif)
natrii acetas trihydricus
- Substance HNIDK
natrium
0.209 MG Substance HBESI
acidum aceticum glaciale
- Substance HNIDK
trehalosum dihydricum
- Substance HNIDK
polysorbatum 20
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK

Reimbursement information

Public price
CHF 3146.40
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/10/2021

Authorization holder

AbbVie AG

6330 Cham

Authorization information

Swissmedic authorization number
66944
Drug name
Skyrizi, lnjektionslösung in einer Fertigspritze
Galenic form
INLFS
ATC Code
L04AC18
Authorization status
Z
Dispensing category
B
First authorization
18/04/2019
Authorization expiration date
31/12/9999
IT Number
07.15.0.
Domain
Human medicine
Field of application
Plaque-Psoriasis bei Erwachsenen, Psoriasis-Arthritis

Package details

Description (FR)
SKYRIZI Sol inj 150 mg/ml Ser prér, 1pce
Description (DE)
SKYRIZI Inj Lös 150 mg/ml Fertspr, 1Stk
Market launch
07/07/2021
Narcotic (BTM)
No

Other package sizes (1)

SKYRIZI Sol inj 75 mg/0.83ml Ser prér, 2pce
2 FESP
GTIN: 7680669440015
View
Buy us a coffee Explore the data